ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

XERS Xeris Biopharma Holdings Inc

1.93
0.07 (3.76%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Xeris Biopharma Holdings Inc XERS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.07 3.76% 1.93 23:00:11
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
1.90 1.84 1.93 1.89 1.86
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
02/5/202406:00BWXeris Biopharma to Report First Quarter 2024 Financial..
03/4/202415:05BWXeris Pharmaceuticals Announces Inducement Grants Under..
02/4/202406:00BWXeris Biopharma to Participate in the 23rd Annual Needham..
06/3/202415:19EDGAR2Form S-8 - Securities to be offered to employees in employee..
06/3/202415:10EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
06/3/202406:27EDGAR2Form 8-K - Current report
06/3/202406:02BWXeris Biopharma Reports Fourth Quarter and Full Year 2023..
06/3/202406:00BWXeris Refinances Its $150M Senior Secured Term Loan Facility..
28/2/202406:00BWXeris Biopharma to Report Fourth Quarter and Full Year 2023..
05/2/202406:00BWXeris to Present at the Oppenheimer 34th Annual Healthcare..
31/1/202416:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202409:12DJNXeris Biopharma Shares Climb 12% on Amgen License Agreement
10/1/202407:53DJNXeris Biopharma Reaches License Agreement With Amgen On..
10/1/202407:00BWXeris Biopharma Enters Into an Exclusive Worldwide License..
05/1/202415:05BWXeris Pharmaceuticals Announces Inducement Grants Under..
04/1/202406:09EDGAR2Form 8-K - Current report
04/1/202406:00BWXeris Biopharma Updates Its Outlook for 2023
27/12/202306:00BWXeris Biopharma to Present at the 42nd Annual J.P. Morgan..
21/11/202315:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/11/202315:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202306:20EDGAR2Form 8-K - Current report
09/11/202306:00BWXeris Biopharma Reports Third Quarter 2023 Financial Results
16/10/202306:12EDGAR2Form 8-K - Current report
16/10/202306:00BWXeris Biopharma Raises Full-Year Financial Guidance and..
29/9/202315:55EDGAR2Form 8-K - Current report
27/9/202307:11EDGAR2Form 8-K - Current report
27/9/202307:00BWXeris Biopharma Announces Private Convertible Note Exchange..
14/9/202315:05BWXeris to Participate in the 2023 Cantor Global Healthcare..
28/8/202306:00BWXeris to Participate at the H.C. Wainwright 25th Annual..
08/8/202315:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202306:23EDGAR2Form 8-K - Current report
08/8/202306:00BWXeris Biopharma Reports Second Quarter 2023 Financial..
01/8/202306:00BWXeris Biopharma to Report Second Quarter 2023 Financial..
31/7/202306:00BWXeris Ships One Millionth Gvoke® Unit
28/6/202315:28EDGAR2Form 8-K - Current report
21/6/202306:00BWXeris Biopharma Announces First Participant Dosed in a Phase..
01/6/202306:00BWXeris Biopharma to Participate at the Jefferies Healthcare..
09/5/202306:00BWXeris Biopharma Reports First Quarter 2023 Financial Results

Su Consulta Reciente

Delayed Upgrade Clock